A5042512945- Lipoproteins and Cardiovascular Health
- Hormonal Regulation and Hypertension
- Computational Drug Discovery Methods
- PI3K/AKT/mTOR signaling in cancer
- Polyamine Metabolism and Applications
- CAR-T cell therapy research
- T-cell and B-cell Immunology
- Chemotherapy-induced cardiotoxicity and mitigation
- Cardiac Imaging and Diagnostics
- Cardiac Ischemia and Reperfusion
- Tuberous Sclerosis Complex Research
- Immunotherapy and Immune Responses
- Autophagy in Disease and Therapy
University of Pennsylvania
2024-2025
Johns Hopkins University
2019-2020
Outcomes of bispecific antibodies in patients with renal impairment (RI) are not well-characterized given the exclusion these from clinical trials. Herein, we evaluated relapsed/refractory multiple myeloma and RI treated standard-of-care teclistamab. was defined as creatinine clearance (CrCl) <40mL/min. CrCl <30mL/min or dialysis dependence were severe RI. Of 384 included patients, 81 (21%) had RI, including 45 (18%) 18 (5%) on dialysis. Patients more likely to be older (median...
Stimulated PKG1α (protein kinase G-1α) phosphorylates TSC2 (tuberous sclerosis complex 2) at serine 1365, potently suppressing mTORC1 (mechanistic [mammalian] target of rapamycin 1) activation by neurohormonal and hemodynamic stress. This reduces pathological hypertrophy dysfunction increases autophagy. oxidation cysteine-42 is also induced these stressors, which blunts its cardioprotective effects.
Abstract Purpose: Preventing Anthracycline Cardiovascular Toxicity with Statins (PREVENT; NCT01988571) randomized patients breast cancer or lymphoma receiving anthracyclines to atorvastatin 40 mg daily placebo. We evaluated the effects of on oxidative and nitrosative stress biomarkers, explored whether these biomarkers could explain lack effect LVEF (left ventricular ejection fraction) in PREVENT. Patients Methods: Blood samples were collected cardiac MRI was performed before doxorubicin...
<div>AbstractPurpose:<p>Preventing Anthracycline Cardiovascular Toxicity with Statins (PREVENT; NCT01988571) randomized patients breast cancer or lymphoma receiving anthracyclines to atorvastatin 40 mg daily placebo. We evaluated the effects of on oxidative and nitrosative stress biomarkers, explored whether these biomarkers could explain lack effect LVEF (left ventricular ejection fraction) in PREVENT.</p>Patients Methods:<p>Blood samples were collected cardiac MRI...
<p>Supplemental Table S1: Study Representativeness Table</p>
<p>Supplemental Table S1: Study Representativeness Table</p>
<div>AbstractPurpose:<p>Preventing Anthracycline Cardiovascular Toxicity with Statins (PREVENT; NCT01988571) randomized patients breast cancer or lymphoma receiving anthracyclines to atorvastatin 40 mg daily placebo. We evaluated the effects of on oxidative and nitrosative stress biomarkers, explored whether these biomarkers could explain lack effect LVEF (left ventricular ejection fraction) in PREVENT.</p>Patients Methods:<p>Blood samples were collected cardiac MRI...
<p>Supplemental Table S2: Factor Loadings for Biomarker Clusters in Principal Component Analysis</p>
<p>Supplemental Table S2: Factor Loadings for Biomarker Clusters in Principal Component Analysis</p>